Cadrenal Therapeutics, Inc. Common Stock

CVKD

$1.21

-5.31%

2026-09-04 12:19:29 EDT-$0.07

Healthcare

Biotechnology

NASDAQ

Active Trading

Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, ...

Financial Highlights of CVKD

Profitability trend

Latest / TTM · 5 periods

Gross Margin

0.0%

Net Margin

0.0%

P/E Ratio

-0.26x

n/a

Debt / Equity

0.00

n/a

Current Ratio

3.73

Dividend Yield

0.0%

Understanding

TTM —

Interest coverage is weak

Financial highlights

Latest / TTM · 5 periods

Snapshot

Latest / TTM: 2026-09-04

Gross Margin

0.0%

Net Margin

0.0%

P/E Ratio

-0.26x

Debt / Equity

0.00

Profitability

Profitability table

Metric	2022	2023	2024	2025	2026
Gross MarginGross profit as a percentage of revenue.	0.0%	0.0%	0.0%	0.0%	—
Operating MarginOperating income as a percentage of revenue.	0.0%	0.0%	0.0%	0.0%	—
Net MarginNet income as a percentage of revenue.	0.0%	0.0%	0.0%	0.0%	—
EBITDA MarginEBITDA divided by revenue.	0.0%	0.0%	0.0%	0.0%	—
Pre-tax MarginPre-tax profit as a percentage of revenue.	0.0%	0.0%	0.0%	0.0%	—

Liquidity & leverage

Liquidity & leverage table

Metric	2022	2023	2024	2025	2026
Current RatioCurrent assets divided by current liabilities.	0.55	10.27	3.77	2.72	—
Quick RatioLiquid assets divided by current liabilities.	0.55	10.27	3.77	2.72	—
Cash RatioCash and equivalents divided by current liabilities.	0.02	10.16	3.73	2.52	—
Debt / AssetsDebt as a share of total assets.	82.3%	0.3%	0.0%	0.0%	—
Debt / EquityDebt compared with shareholder equity.	-0.12	0.00	0.00	0.00	—

Operating efficiency

Operating efficiency table

Metric	2022	2023	2024	2025	2026
Receivables TurnoverHow often receivables are collected in a year.	0.00x	0.00x	0.00x	0.00x	—
Inventory TurnoverHow often inventory is sold in a year.	0.00x	0.00x	0.00x	0.00x	—
Payables TurnoverHow often payables are paid in a year.	0.00x	0.00x	0.00x	0.00x	—
Asset TurnoverRevenue generated per dollar of assets.	0.00x	0.00x	0.00x	0.00x	—
Working Capital TurnoverRevenue generated per dollar of working capital.	0.00x	0.00x	0.00x	0.00x	—

Valuation ratios

Valuation ratios table

Metric	2022	2023	2024	2025	2026
P/E RatioPrice paid for each dollar of earnings.	-7.14x	-1.15x	-1.66x	-1.02x	—
P/B RatioPrice paid for each dollar of book value.	-8.64x	1.25x	2.38x	4.94x	—
P/S RatioPrice paid for each dollar of sales.	0.00x	0.00x	0.00x	0.00x	—
P/FCF RatioPrice paid for each dollar of free cash flow.	-36.40x	-2.73x	-2.40x	-1.07x	—
Dividend YieldAnnual dividend divided by current share price.	0.0%	0.0%	0.0%	0.0%	—

Supply Chain of CVKD

RELATIONS

Upstream

Undisclosed CDMO / API ManufacturerUndisclosed Clinical CROSpecialty Chemical Suppliers (Unidentified)

Downstream

No Commercial Customers (Pre-Revenue Stage)Potential Future Commercialization Partner(s)

Proxies

Esperion TherapeuticsNASDAQ:ESPR Annexon BiosciencesNASDAQ:ANNX Acumen PharmaceuticalsNASDAQ:ABOS

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer